Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent

Girieca Lorusso, Nicola Vannini, Ilaria Sogno, Luca Generoso, Spiridione Garbisa, Douglas M. Noonan, Adriana Albini

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Hyperforin, the major lipophilic compound contained in extracts of Hypericum perforatum, is responsible for the antidepressant activity associated with the extract. Recently, several other biological properties of Hyperforin have been unveiled including inhibition of tumour invasion and angiogenesis. The mechanism of the anti-angiogenic activity of Hyperforin remains to be fully elucidated. We show that treatment with non-cytotoxic concentrations of Hyperforin restrains, in a dose-dependent manner, the capacity of endothelial cells to migrate towards relevant chemotactic stimuli. Hyperforin inhibits the organisation of HUVE endothelial cells in capillary-like structures in vitro, and potently represses angiogenesis in vivo in the Matrigel sponge assay in response to diverse angiogenic agents. Immunofluorescent staining shows that in cytokine-activated endothelial HUVE cells Hyperforin prevents translocation to the nucleus of NF-κB, a transcription factor regulating numerous genes involved in cell growth, survival, angiogenesis and invasion. Under Hyperforin treatment in vivo, the growth of Kaposi's sarcoma - a highly angiogenic tumour - is strongly inhibited, with the resultant tumours remarkably reduced in size and in vascularisation as compared with controls. Hyperforin has also been reported to have anti-inflammatory properties. Here we show that Hyperforin inhibits neutrophil and monocyte chemotaxis in vitro and angiogenesis in vivo induced by angiogenic chemokines (CXCL8 or CCL2). These results highlight the potential for Hyperforin as an anti-inflammatory angioprevention agent, acting as a strong inhibitor of inflammation- or tumour-triggered angiogenesis, and provide new therapeutic approaches to halting pathology-associated angiogenesis.

Original languageEnglish
Pages (from-to)1474-1484
Number of pages11
JournalEuropean Journal of Cancer
Volume45
Issue number8
DOIs
Publication statusPublished - May 2009

Fingerprint

Endothelial Cells
Neoplasms
Anti-Inflammatory Agents
hyperforin
Hypericum
Chemokine CCL2
Kaposi's Sarcoma
Porifera
Chemotaxis
Growth
Interleukin-8
Antidepressive Agents
Monocytes
Cell Survival
Neutrophils
Transcription Factors
Therapeutics
Pathology
Staining and Labeling
Cytokines

Keywords

  • Angiogenesis
  • Chemoprevention
  • Endothelial cells
  • Hyperforin
  • Inflammation
  • Monocytes
  • Neutrophils

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent. / Lorusso, Girieca; Vannini, Nicola; Sogno, Ilaria; Generoso, Luca; Garbisa, Spiridione; Noonan, Douglas M.; Albini, Adriana.

In: European Journal of Cancer, Vol. 45, No. 8, 05.2009, p. 1474-1484.

Research output: Contribution to journalArticle

Lorusso, Girieca ; Vannini, Nicola ; Sogno, Ilaria ; Generoso, Luca ; Garbisa, Spiridione ; Noonan, Douglas M. ; Albini, Adriana. / Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent. In: European Journal of Cancer. 2009 ; Vol. 45, No. 8. pp. 1474-1484.
@article{7ee4690aeb9c46c39ae437b3e48edda6,
title = "Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent",
abstract = "Hyperforin, the major lipophilic compound contained in extracts of Hypericum perforatum, is responsible for the antidepressant activity associated with the extract. Recently, several other biological properties of Hyperforin have been unveiled including inhibition of tumour invasion and angiogenesis. The mechanism of the anti-angiogenic activity of Hyperforin remains to be fully elucidated. We show that treatment with non-cytotoxic concentrations of Hyperforin restrains, in a dose-dependent manner, the capacity of endothelial cells to migrate towards relevant chemotactic stimuli. Hyperforin inhibits the organisation of HUVE endothelial cells in capillary-like structures in vitro, and potently represses angiogenesis in vivo in the Matrigel sponge assay in response to diverse angiogenic agents. Immunofluorescent staining shows that in cytokine-activated endothelial HUVE cells Hyperforin prevents translocation to the nucleus of NF-κB, a transcription factor regulating numerous genes involved in cell growth, survival, angiogenesis and invasion. Under Hyperforin treatment in vivo, the growth of Kaposi's sarcoma - a highly angiogenic tumour - is strongly inhibited, with the resultant tumours remarkably reduced in size and in vascularisation as compared with controls. Hyperforin has also been reported to have anti-inflammatory properties. Here we show that Hyperforin inhibits neutrophil and monocyte chemotaxis in vitro and angiogenesis in vivo induced by angiogenic chemokines (CXCL8 or CCL2). These results highlight the potential for Hyperforin as an anti-inflammatory angioprevention agent, acting as a strong inhibitor of inflammation- or tumour-triggered angiogenesis, and provide new therapeutic approaches to halting pathology-associated angiogenesis.",
keywords = "Angiogenesis, Chemoprevention, Endothelial cells, Hyperforin, Inflammation, Monocytes, Neutrophils",
author = "Girieca Lorusso and Nicola Vannini and Ilaria Sogno and Luca Generoso and Spiridione Garbisa and Noonan, {Douglas M.} and Adriana Albini",
year = "2009",
month = "5",
doi = "10.1016/j.ejca.2009.01.014",
language = "English",
volume = "45",
pages = "1474--1484",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "8",

}

TY - JOUR

T1 - Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent

AU - Lorusso, Girieca

AU - Vannini, Nicola

AU - Sogno, Ilaria

AU - Generoso, Luca

AU - Garbisa, Spiridione

AU - Noonan, Douglas M.

AU - Albini, Adriana

PY - 2009/5

Y1 - 2009/5

N2 - Hyperforin, the major lipophilic compound contained in extracts of Hypericum perforatum, is responsible for the antidepressant activity associated with the extract. Recently, several other biological properties of Hyperforin have been unveiled including inhibition of tumour invasion and angiogenesis. The mechanism of the anti-angiogenic activity of Hyperforin remains to be fully elucidated. We show that treatment with non-cytotoxic concentrations of Hyperforin restrains, in a dose-dependent manner, the capacity of endothelial cells to migrate towards relevant chemotactic stimuli. Hyperforin inhibits the organisation of HUVE endothelial cells in capillary-like structures in vitro, and potently represses angiogenesis in vivo in the Matrigel sponge assay in response to diverse angiogenic agents. Immunofluorescent staining shows that in cytokine-activated endothelial HUVE cells Hyperforin prevents translocation to the nucleus of NF-κB, a transcription factor regulating numerous genes involved in cell growth, survival, angiogenesis and invasion. Under Hyperforin treatment in vivo, the growth of Kaposi's sarcoma - a highly angiogenic tumour - is strongly inhibited, with the resultant tumours remarkably reduced in size and in vascularisation as compared with controls. Hyperforin has also been reported to have anti-inflammatory properties. Here we show that Hyperforin inhibits neutrophil and monocyte chemotaxis in vitro and angiogenesis in vivo induced by angiogenic chemokines (CXCL8 or CCL2). These results highlight the potential for Hyperforin as an anti-inflammatory angioprevention agent, acting as a strong inhibitor of inflammation- or tumour-triggered angiogenesis, and provide new therapeutic approaches to halting pathology-associated angiogenesis.

AB - Hyperforin, the major lipophilic compound contained in extracts of Hypericum perforatum, is responsible for the antidepressant activity associated with the extract. Recently, several other biological properties of Hyperforin have been unveiled including inhibition of tumour invasion and angiogenesis. The mechanism of the anti-angiogenic activity of Hyperforin remains to be fully elucidated. We show that treatment with non-cytotoxic concentrations of Hyperforin restrains, in a dose-dependent manner, the capacity of endothelial cells to migrate towards relevant chemotactic stimuli. Hyperforin inhibits the organisation of HUVE endothelial cells in capillary-like structures in vitro, and potently represses angiogenesis in vivo in the Matrigel sponge assay in response to diverse angiogenic agents. Immunofluorescent staining shows that in cytokine-activated endothelial HUVE cells Hyperforin prevents translocation to the nucleus of NF-κB, a transcription factor regulating numerous genes involved in cell growth, survival, angiogenesis and invasion. Under Hyperforin treatment in vivo, the growth of Kaposi's sarcoma - a highly angiogenic tumour - is strongly inhibited, with the resultant tumours remarkably reduced in size and in vascularisation as compared with controls. Hyperforin has also been reported to have anti-inflammatory properties. Here we show that Hyperforin inhibits neutrophil and monocyte chemotaxis in vitro and angiogenesis in vivo induced by angiogenic chemokines (CXCL8 or CCL2). These results highlight the potential for Hyperforin as an anti-inflammatory angioprevention agent, acting as a strong inhibitor of inflammation- or tumour-triggered angiogenesis, and provide new therapeutic approaches to halting pathology-associated angiogenesis.

KW - Angiogenesis

KW - Chemoprevention

KW - Endothelial cells

KW - Hyperforin

KW - Inflammation

KW - Monocytes

KW - Neutrophils

UR - http://www.scopus.com/inward/record.url?scp=65249172014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249172014&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2009.01.014

DO - 10.1016/j.ejca.2009.01.014

M3 - Article

C2 - 19223175

AN - SCOPUS:65249172014

VL - 45

SP - 1474

EP - 1484

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 8

ER -